Nimotop (Nimodipine)

Nimotop acts on cerebral vasculature to prevent vasospasm after subarachnoid hemorrhage.

• Prevention of cerebral vasospasm following subarachnoid hemorrhage: reduces the risk of delayed ischemic neurological deficits.
• Management of secondary cerebral ischemia after hemorrhage: supports cerebral blood flow during the critical post‑bleed period.
• Adjunct in neurocritical care: contributes to overall neuroprotection strategies in intensive care settings.

• Nimodipine antagonizes L‑type calcium channels on vascular smooth muscle, preferentially in cerebral arteries. This blockade reduces calcium influx, leading to selective vasodilation of cerebral vessels while sparing systemic circulation, thereby improving cerebral perfusion and providing neuroprotective effects during the vulnerable period after subarachnoid hemorrhage.

Nimotop may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Headache: mild to moderate discomfort.
• Dizziness or light‑headedness: often related to blood pressure changes.
• Flushing: transient warmth and redness of skin.
• Nausea or vomiting: gastrointestinal upset.
• Hypotension: lower than normal blood pressure.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Bradycardia: unusually slow heart rate.
• Allergic reactions: rash, itching, or swelling.
• Hepatic dysfunction: elevated liver enzymes.
• Neutropenia or leukopenia: reduced white blood cell counts.
• Myocardial ischemia: chest pain or cardiac events.

Before prescribing Nimotop, clinicians should consider several safety measures.

• Monitor blood pressure: watch for hypotension, especially after the first doses.
• Use caution in hepatic impairment: adjust therapy if liver function is compromised.
• Avoid abrupt discontinuation: taper to prevent rebound vasospasm.
• Review concomitant vasodilators: assess additive hypotensive effects.
• Caution with strong CYP3A4 inhibitors: dose may need adjustment.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nimotop can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of toxicity.
• Co‑administration with other potent vasodilators (e.g., nitroglycerin): can cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.

• Other calcium channel blockers: additive vasodilatory action may lower blood pressure.
• Beta‑blockers: combined use may lead to bradycardia.
• Diuretics: may enhance hypotensive response.
• Antihypertensive agents: monitor for excessive blood pressure reduction.